Pacific Biosciences Of California (PACB) Research & Development (2010 - 2026)

Pacific Biosciences Of California's Research & Development history runs 17 years deep, the most recent figure standing at $19.6 million for Q1 2026.

• On a quarterly basis, Research & Development fell 32.51% year-over-year to $19.6 million in Q1 2026; TTM through Mar 2026 was $87.9 million, a 27.1% decrease from a year earlier, with the FY2025 full-year figure at $97.3 million, down 27.88% from the prior year.
• Research & Development eased to $19.6 million in Q1 2026 per PACB's latest filing, from $22.9 million in the prior quarter.
• Across five years, Research & Development topped out at $52.9 million in Q1 2022 and bottomed at $19.6 million in Q1 2026.
• The 5-year median for Research & Development is $42.6 million (2022), against an average of $37.2 million.
• Across the five-year window, Research & Development soared 157.63% in 2022 and tumbled 46.3% in 2024, its largest moves.
• Year by year, Research & Development stood at $42.6 million in 2022, then rose by 4.51% to $44.5 million in 2023, then slumped by 38.34% to $27.5 million in 2024, then retreated by 16.7% to $22.9 million in 2025, then retreated by 14.3% to $19.6 million in 2026.
• Per Business Quant, the three latest PACB Research & Development figures stand at $19.6 million (Q1 2026), $22.9 million (Q4 2025), and $22.8 million (Q3 2025).